Azucena Espars-Ogando

List of Publications by Citations

Source: https://exaly.com/author-pdf/9360014/azucena-esparis-ogando-publications-by-citations.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37 papers	1,750 citations	24 h-index	38 g-index
38 ext. papers	1,966 ext. citations	6.2 avg, IF	4.02 L-index

#	Paper	IF	Citations
37	Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. *Molecular Biology of the Cell*, **2002**, 13, 2031-44	3.5	251
36	Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. *Molecular and Cellular Neurosciences*, **2000**, 16, 631-48	4.8	147
35	Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. *Molecular and Cellular Biology*, **2002**, 22, 270-85	4.8	144
34	Neuregulins and cancer. *Clinical Cancer Research*, **2008**, 14, 3237-41	12.9	81
33	Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. *PLoS ONE*, **2009**, 4, e5565	3.7	76
32	Multifunctional role of Erk5 in multiple myeloma. *Blood*, **2005**, 105, 4492-9	2.2	70
31	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. *Oncogene*, **2014**, 33, 148-56	9.2	67
30	Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. *Stem Cells*, **2013**, 31, 1075-85	5.8	67
29	Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. *Cancer Research*, **2005**, 65, 6801-10	10.1	59
28	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. *Biochemical Journal*, **2000**, 346, 359-367	3.8	57
27	Bortezomib is an efficient agent in plasma cell leukemias. *International Journal of Cancer*, **2005**, 114, 665-7	7.5	52
26	Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 2656-63	2.2	51
25	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. *Annals of Oncology*, **2008**, 19, 1860-9	10.3	49
24	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. *Biochemical Journal*, **2002**, 363, 211-221	3.8	47
23	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. *Gut*, **2015**, 64, 1454-65	19.2	45
22	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. *European Journal of Neuroscience*, **1999**, 11, 1421-30	3.5	41
21	Potent antimyeloma activity of a novel ERK5/CDK inhibitor. *Clinical Cancer Research*, **2013**, 19, 2677-87	12.9	38

20	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. *Biochemical Journal*, **2002**, 363, 211-21	3.8	37
19	ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. *PLoS ONE*, **2009**, 4, e6124	3.7	35
18	Therapeutic potential of ERK5 targeting in triple negative breast cancer. *Oncotarget*, **2014**, 5, 11308-18	3.3	35
17	Targeting the EGF/HER Ligand-Receptor System in Cancer. *Current Pharmaceutical Design*, **2016**, 22, 5887-5898	3.3	35
16	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 383	12.8	32
15	ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. *Neoplasia*, **2013**, 15, 649-59	6.4	30
14	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. *Oncogene*, **2017**, 36, 1733-1744	9.2	28
13	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. *Cellular Signalling*, **2007**, 19, 1473-87	4.9	24
12	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. *Nephrology Dialysis Transplantation*, **2008**, 23, 3403-11	4.3	22
11	The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. *Molecular Biology of the Cell*, **2007**, 18, 380-93	3.5	22
10	Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway. *Cancer Research*, **2019**, 79, 2244-2256	10.1	20
9	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. *Biochemical Journal*, **1999**, 344, 339-348	3.8	19
8	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. *Biochemical Journal*, **2000**, 346, 359	3.8	18
7	Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies. *Oncotarget*, **2016**, 7, 45042-45051	3.3	14
6	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. *Frontiers in Immunology*, **2019**, 10, 2802	8.4	13
5	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. *Biochemical Journal*, **1999**, 344, 339	3.8	8
4	MEK5 promotes lung adenocarcinoma. *European Respiratory Journal*, **2019**, 53,	13.6	5
3	Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21. *Cancer Research*, **2021**,	10.1	4

2	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. *Npj Precision Oncology*, **2021**, 5, 78	9.8	4
1	Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. *Journal of Biochemistry*, **2005**, 137, 731-9	3.1	3